|Bid||60.78 x 800|
|Ask||62.28 x 800|
|Day's range||60.95 - 61.74|
|52-week range||60.71 - 86.29|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||42.72|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The news comes after Bloomberg reported that the bank has been weighing a range of strategic options amid concerns about its financial health.
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Raytheon Technologies Corporation (RTX) and BP p.l.c. (BP).
Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.